|
|
|
|
| LEADER |
03664nmm a2200277 u 4500 |
| 001 |
EB000634982 |
| 003 |
EBX01000000000000000488064 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9781592597208
|
| 100 |
1 |
|
|a Hickman, John A.
|e [editor]
|
| 245 |
0 |
0 |
|a Apoptosis and Cancer Chemotherapy
|h Elektronische Ressource
|c edited by John A. Hickman, Caroline Dive
|
| 250 |
|
|
|a 1st ed. 1999
|
| 260 |
|
|
|a Totowa, NJ
|b Humana
|c 1999, 1999
|
| 300 |
|
|
|a XV, 342 p. 24 illus
|b online resource
|
| 505 |
0 |
|
|a 1 Does Apoptosis Contribute to Tumor Cell Sensitivity to Anticancer Agents? -- 2 p53, Apoptosis, and Chemotherapy -- 3 The Role of p53 in Chemosensitivity -- 4 Function of the p53 Gene Family: A Holistic Perspective -- 5 Mismatch Repair Deficiency, Apoptosis, and Drug Resistance -- 6 Involvement of c-Abl Tyrosine Kinase in Apoptotic Response to Anticancer Agents -- 7 Bcl-2 Family Proteins: Relative Importance as Determinants of Chemoresistance in Cancer -- 8 Bax, a Death Effector Molecule: Its Role in Development and Oncogenesis -- 9 Bax, a Proapoptotic Protein Forming Channels in Mitochondria -- 10 Mechanism of Action of the Proapoptotic Gene Bak -- 11 Killers or Clean-Up Crew: How Central Are the Central Mechanisms of Apoptosis? -- 12 Role of CD95 (APO-1/Fas) System in Chemotherapy -- 13 Insulin-Like Growth Factor-1 Receptor as a Target for Anticancer Therapy -- 14 Drug Resistance and the Survival Niche: Survival Signals Combine to Suppress Drug-Induced Apoptosis in B-Lymphoma Cells -- 15 Chemotherapy, Tumor Microenvironment, and Apoptosis -- 16 Molecular Regulation and Therapeutic Implications of Cell Death in Prostate Cancer -- 17 Chemotherapy and Apoptosis in the Ovary: Cancer Treatment Comes with a Price -- 18 Role of Bcl-2 Family Members in Homeostasis, in Toxicology in Normal Intestine, and for Prognosis of Colonic Carcinomas -- 19 Apoptosis and Breast Cancer -- 20 Role of Apoptosis in Human Neuroblastomas -- 21 Response of Testicular Tumors to Chemotherapy: Relative Role of Drug—DNA Interactions and Apoptosis -- Concluding Remarks: Has the Information Explosion on Apoptosis Affected Clinical Practice?
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Dive, Caroline
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Cancer Drug Discovery and Development
|
| 028 |
5 |
0 |
|a 10.1007/978-1-59259-720-8
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-59259-720-8?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a The past few years have witnessed an astonishing international effort that established the role of some 20 new molecules in apoptosis and added activation or suppression of apoptosis to the accepted biological functions of a great many others already familiar in cancer biology. Some of these molecules are receptors, transducing cytokine-mediated signals; others appear to intensify or diminish the risk that a compro mised cell will fire its apoptosis effector mechanism. All are of interest as potential targets for tumor therapy, and some may prove to be control points influenced in the pathogenesis of cancer and other diseases as diverse as viral infection, neurodegenerative disorders, and stroke. Sometimes, in the midst of these developments, a kind of euphoria ap pears to have gripped the research community, with the expectation that apoptosis will afford explanations to many unsolved questions in cellu lar regulation. This book, in a series of thoughtful and provocative ar ticles--some from established leaders in the field, and others from younger scientists--seeks to redress the balance
|